Working… Menu

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF (SCENIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03864328
Recruitment Status : Terminated (COVID-19 Pandemic)
First Posted : March 6, 2019
Last Update Posted : June 11, 2020
Respivant Sciences Inc.
Information provided by (Responsible Party):
Respivant Sciences Inc. ( Respivant Sciences GmbH )

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 29, 2020
Actual Study Completion Date : June 5, 2020